DE  |  EN
Home   |  Contact
Home > Company > Research & development

Research & development

Every day closer to our goal

TETEC AG operates an extensive research & development program together with a number of prestigious national and international cooperation partners from the worlds of hospitals, universities and industry.

Injectable and “intelligent” biomaterials
Working together with our partners, we have developed a highly compatible injectable and in situ polymerizable biomaterial with intelligent properties.  A hydrogel, it has many advantages, including anti-inflammatory, vessel- and bone-inhibiting and hydraulic properties. Together with defined cell populations and other regeneration promoters, it can be used under minimally invasive conditions for cartilage and, in particular, disc regeneration. The biomaterial fixes the cells in the defect area, increasing their survival rate through environmental conditioning and additionally addressing a series of concomitant pathologies regularly observed with intervertebral disc regeneration. In addition, it serves as a modifiable platform technology for the development of further therapeutic approaches in the area of regenerative medicine. The biomaterial is already being used today in suitable indications under the product name NOVOCART Inject, for purely arthroscopic ACT treatments.
Mesenchymal stem cells
New markers and methods for the identification and purification of adult mesenchymal stem cells (MSC) for biological cartilage and bone reconstruction are currently being explored in a separate development project. Within this project, one particularly interesting sub-population of mesenchymal stem cells has been identified which indicates high regenerative potential and which can also be differentiated from chrondrogenic cells, that is cells with cartilage or disc properties. Through further analysis, we have been able to show that, even among older patients, MSCs can still be isolated in sufficient quantities and quality using suitable methods. The results of this study were sufficiently promising to merit the Young Investigator Award of the Osteoarthritis Research Society International (OARSI).  

Treatment of degenerative cartilage damage
Given the knowledge that over 200 million people worldwide are affected by degenerative skeletal diseases, that in Europe and the USA combine a total of almost two million arthroscopic operations are carried out each year, and that approximately 35,000 knee endoprostheses are implanted each year, there remains much to do if we are to intervene on a meaningful scale in remedying such problems.  Our medium-term aim is to be able to reliably treat even major cartilage damage brought about by degenerative changes. We have already taken a significant step in the right direction by developing NOVOCART® 3D and our intelligent biomaterials. Combining these two biomaterials should allow for an extension of the indication to the regeneration of degeneratively caused cartilage damage.

Meniscus and biological bone replacement
Working in conjunction with our cooperation partners, we have developed a new active (in vitro) or passive (in vivo) colonizable biomaterial for partial or full meniscus replacement. This procedure is expected to further improve the chances of retaining the knee joint.